Natural cannabidiol is extracted from the cannabis plant. The medicaments are formulated for parenteral, oral, and transdermal administration and can also be used as a safe and effective therapy for treatment and prevention diabetes.

Natural cannabidiol is extracted from the cannabis plant. The medicaments are formulated for parenteral, oral, and transdermal administration and can also be used as a safe and effective therapy for treatment and prevention diabetes.

Cannabidiol (CBD) treatment significantly reduces the incidence of diabetes

Category	Diabetes
Development Stage	Broad in-vivo results
Patent Status	Patent Pending
Market Size	20.8 million children and adults in the US suffer from diabetes. Of those, 1.3 million are Type I diabetes patients.

Highlights

• The use of Cannabidiol (CBD) provides a novel preventive measure of Type I diabetes.
• In vivo studies show that CBD treatment significantly reduces the incidence of diabetes in non-obese diabetic (NOD) mice from an incidence of 86% to 30%.
• CBD is a non-psychoactive Cannabidinoid, which is a component of the Cannabis Sativa (marijuana) plant. Cannabidinoids have been previously shown to be capable of suppressing inflammation and various aspects of cell-mediated immunity.

Our Innovation

Type I diabetes affects millions of people worldwide with no available cure or preventive treatment. The use of CBD will inhibit partly through anti-inflammatory activity the destruction of insulitis-beta cells which are responsible for the production of insulin, thus preventing the occurrence of type I diabetes.

Key Features

• Known and familiar non-toxic compound
• Simple oral administration
• High efficacy in preventing Type 1 diabetes, allowing for reduced complications and patient mortality
• Potential contribution to decreasing the annual economic burden of diabetes, estimated to reach $132 billion [1].
• High manufacturability, allowing for flexibility in pricing strategy

Development Milestones

• Efficacy studies of CBD in NOD mice at the initial stages of Type I diabetes
• Clinical studies.

The Opportunity

• 1.3 million Patients are currently diagnosed with Type I diabetes in the US with an additional 75,000 to 150,000 patients diagnosed each year.
• The proposed drug offers an effective preventive treatment for Type I diabetes which can dramatically reduce the rate of the disease and its associated complications and mortality.

[1] American Diabetes Association, 2002 statistics

project-id 7-2006-321

Early Stage

Patent Pending